Advertisement
News
Subscribe to MDT Magazine News

Medco Health will report 4Q results Tuesday(2)

February 18, 2011 4:46 am | by The Associated Press | Comments

Pharmacy benefits manager Medco Health Solutions Inc. reports its fourth-quarter results before the stock market opens Tuesday.WHAT TO WATCH FOR: Medco manages prescription drug benefits for health plan sponsors and members. Wall Street will be watching the company's success at winning new...

Medco Health will report 4Q results Tuesday

February 18, 2011 4:45 am | Comments

Pharmacy benefits manager Medco Health Solutions Inc. reports its fourth-quarter results before the stock market opens Tuesday.WHAT TO WATCH FOR: Medco manages prescription drug benefits for health plan sponsors and members. Wall Street will be watching the company's success at winning new...

Life Technologies Announces Visionary Winners of the Ion Torrent PGM Grants Program in Europe

February 18, 2011 3:38 am | by Bio-Medicine.Org | Comments

CARLSBAD, Calif., Feb. 18, 2011 /- Life Technologies Corporation (Nasdaq: LIFE ), today announced Dr. Angel Carracedo and Dr. Mark Pallen as the winners of the European Ion Torrent Personal Genome Machine (PGM™) Sequencer Grants Program.   (Logo:  ...

TOPICS:
Advertisement

Clinical Responses Demonstrated in Metastatic Castrate Resistant Prostate Cancer Patients Treated With BPX-101 Cancer Vaccine

February 18, 2011 3:38 am | by Bio-Medicine.Org | Comments

ORLANDO, Fla., Feb. 18, 2011 /- Bellicum Pharmaceuticals, Inc. today announced the presentation of Phase I/II safety and efficacy data for BPX-101, a novel drug-activated dendritic cell vaccine for metastatic castrate resistant prostate cancer (mCRPC), in three separate posters at the...

TOPICS:

NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting

February 18, 2011 3:37 am | by Bio-Medicine.Org | Comments

ROCKVILLE, Md., Feb. 18, 2011 /- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage biopharmaceutical company, today presented the final safety and immunogenicity results from its 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine clinical trial in Mexico at the invitation-only 7th...

TOPICS:

Zimmer Announces Early Clinical Success of Zimmer® MotionLoc™ Screw Implantation

February 18, 2011 3:37 am | by Bio-Medicine.Org | Comments

SAN DIEGO, Feb. 18, 2011 /- Zimmer Holdings, Inc. (NYSE: ZMH ; SIX: ZMH), a global leader in musculoskeletal care, today announced that early clinical results of the first patients treated with Zimmer MotionLoc™ Screws were free of complications.  The Zimmer MotionLoc Screw is...

TOPICS:

Zimmer Spine Introduces Industry's First Porous Metal Cervical Interbody Device

February 18, 2011 3:37 am | by Bio-Medicine.Org | Comments

SAN DIEGO, Feb. 18, 2011 /- Zimmer Holdings, Inc. (NYSE: ZMH ; SIX: ZMH), a leader in musculoskeletal care, today announced it has received FDA clearance for the TM-S Trabecular Metal™ Cervical Interbody Fusion Device.  The TM-S system is the industry's first cervical interbody...

TOPICS:

Boston Scientific Launches PROMUS® Elementâ„¢ and TAXUS® Elementâ„¢ Stent Systems in India

February 18, 2011 3:36 am | by Boston Scientific | Comments

Company's third-generation drug-eluting stents now available in rapidly growing market

TOPICS:
Advertisement

MAP Pharmaceuticals Appoints Scott R. Ward as Chairman of the Board of Directors

February 18, 2011 3:36 am | by Bio-Medicine.Org | Comments

MOUNTAIN VIEW, Calif., Feb. 18, 2011 /- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced the appointment of Scott R. Ward as Chairman of its Board of Directors. Steven A. Elms, the incumbent Chairman and an original venture capital investor in the Company, will step down from the...

TOPICS:

Fujifilm's Synapse® Mobility Extends Imaging Reach

February 18, 2011 3:36 am | by Bio-Medicine.Org | Comments

STAMFORD, Conn., Feb. 18, 2011 /- FUJIFILM Medical Systems U.S.A., Inc. will be showcasing Synapse® Mobility*, its zero footprint mobile application enabling remote access to Fujifilm's suite of Synapse products from hand-held mobile devices, as well as Macintosh- or Windows-based...

TOPICS:

China Medical Technologies Reports Third Fiscal Quarter Financial Results

February 18, 2011 3:33 am | by Bio-Medicine.Org | Comments

BEIJING, Feb. 18, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED ), a leading China-based advanced in-vitro diagnostic ("IVD") company, announced its unaudited financial results for the third fiscal quarter ended December 31, 2010 ("3Q...

TOPICS:

Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 in Adults With Chronic Genotype 1 HCV

February 18, 2011 1:35 am | by Bio-Medicine.Org | Comments

CORK, Ireland, Feb. 18, 2011 /- Tibotec Pharmaceuticals announced today that two global, registrational phase 3 trials are recruiting patients to examine TMC435, its investigational hepatitis C protease inhibitor, in treatment-naive adults with chronic genotype 1 hepatitis C virus (HCV)....

TOPICS:

Golden Meditech to Form Strategic Alliance with Long Bon International

February 18, 2011 1:35 am | by Bio-Medicine.Org | Comments

TAIPEI, Feb. 18, 2011 /PRNewswire-Asia-FirstCall/ -- Golden Meditech Holdings ("Golden Meditech," 0801.HK, 910801.TW) and Long Bon International Co., Limited ("Long Bon International") today announced that the companies have entered into a memorandum of understanding (MOU) for strategic...

TOPICS:

Australia to host IOF Regionals - 2nd Asia-Pacific Osteoporosis and Bone Meeting

February 17, 2011 11:34 pm | by International Osteoporosis Foundation | Comments

IOF is pleased to announce the 2nd Asia-Pacific Osteoporosis and Bone Meeting, to be held in conjunction with the Australian & New Zealand Bone & Mineral Society (ANZBMS) Annual Scientific Meeting and with the Japanese Bone and Mineral Research Society

TOPICS:

Competing risks analysis highlights new targets in preventing ESRD and death of diabetics

February 17, 2011 9:32 pm | by EurekAlert | Comments

(University of Helsinki) Many patients with Type 1 diabetes and overt nephropathy develop End-Stage Renal Disease (ESRD) and/or succumb to a premature death. The competing risks of death and ESRD may confound the estimates of risk for each outcome. Now, the researchers have...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading